Physitrack PLC (PTRK.ST)
SEK 8.72
(4.06%)
SEK 8.72
(4.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.08 Million EUR | -106.39% |
| 2022 | 2.57 Million EUR | 141.44% |
| 2021 | 1.06 Million EUR | -42.34% |
| 2020 | 1.6 Million EUR | 237.82% |
| 2019 | 546.84 Thousand EUR | 53.71% |
| 2018 | 355.76 Thousand EUR | 197.93% |
| 2017 | - EUR | 39.17% |
| 2016 | - EUR | -125034.73% |
| 2015 | 478.00 EUR | 785.19% |
| 2014 | 54.00 EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.05 Million EUR | -79.91% |
| 2024 Q2 | 891.91 Thousand EUR | -26.74% |
| 2023 Q4 | -4.84 Million EUR | -686.39% |
| 2023 Q1 | 922.09 Thousand EUR | -30.25% |
| 2023 Q2 | 712.27 Thousand EUR | -22.75% |
| 2023 Q3 | 825.65 Thousand EUR | 15.92% |
| 2023 FY | - EUR | -106.39% |
| 2022 Q3 | 714.43 Thousand EUR | 169.15% |
| 2022 Q1 | 734.62 Thousand EUR | 89.87% |
| 2022 FY | - EUR | 141.44% |
| 2022 Q4 | 1.32 Million EUR | 85.05% |
| 2022 Q2 | 265.43 Thousand EUR | -63.87% |
| 2021 Q1 | 605.1 Thousand EUR | 2.17% |
| 2021 FY | - EUR | -42.34% |
| 2021 Q4 | 386.9 Thousand EUR | -14.1% |
| 2021 Q3 | 450.41 Thousand EUR | 167.47% |
| 2021 Q2 | -667.57 Thousand EUR | -210.32% |
| 2020 FY | - EUR | 237.82% |
| 2020 Q4 | 592.28 Thousand EUR | 6.54% |
| 2020 Q3 | 555.9 Thousand EUR | 13.64% |
| 2020 Q2 | 489.16 Thousand EUR | 129.32% |
| 2020 Q1 | 213.31 Thousand EUR | 0.0% |
| 2019 FY | - EUR | 53.71% |
| 2018 FY | - EUR | 197.93% |
| 2017 FY | - EUR | 39.17% |
| 2016 FY | - EUR | -125034.73% |
| 2015 FY | - EUR | 785.19% |
| 2014 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aino Health AB (publ) | -7.52 Million SEK | 194.116% |
| Bonzun AB (publ) | -28.58 Million SEK | 124.789% |
| Kontigo Care AB (publ) | 1.67 Million SEK | -322.287% |
| Medhelp Care Aktiebolag (publ) | 10 Million SEK | 29.154% |
| RaySearch Laboratories AB (publ) | 405.93 Million SEK | 98.254% |
| Surgical Science Sweden AB (publ) | 246.9 Million SEK | 97.13% |